#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16064	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2186	732.0	0	.	n	.	0	C451T	SNP	451	451	C	753	753	T	922	T,C	634,242	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16064	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2186	732.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1486	1486	C	955	C	883	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29530	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3371	871.0	0	.	n	.	0	T695C	SNP	695	695	T	918	918	C	912	C,T	850,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29530	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3371	871.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2194	2194	C	907	C,T	837,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29530	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3371	871.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2268	2268	A	880	A	835	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29530	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3371	871.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	2820	2820	C	901	C,T	853,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29530	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3371	871.0	0	HET	.	.	.	A1638G	.	1638	1638	A	1861	1861	A	926	A,G	460,406	.	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2160	folP	855	855	100.0	folP.l15.c4.ctg.1	1512	142.0	1	SNP	p	R229S	1	.	.	685	687	AGC	980	982	AGC	220;221;219	A;G;C	208;209;208	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5500	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3507	156.4	1	SNP	p	S91F	1	.	.	271	273	TTC	600	602	TTC	167;168;169	T;T;C	152;151;152	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5500	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3507	156.4	1	SNP	p	G95N	0	.	.	283	285	GGC	612	614	GGC	171;169;165	G;G;C	154;153;152	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5500	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3507	156.4	1	SNP	p	D95G	1	.	.	283	285	GGC	612	614	GGC	171;169;165	G;G;C	154;153;152	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1728	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1364	126.4	1	SNP	p	G45D	0	.	.	133	135	GGC	529	531	GGC	213;212;212	G,T;G;C	202,1;200;201	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	862	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	903	94.8	0	.	n	.	0	A197.	DEL	197	197	A	550	550	A	200	A	187	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6444	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2858	224.5	1	SNP	p	D86N	0	.	.	256	258	GAC	583	585	GAC	286;284;283	G;A;C,T	271;263;267,1	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6444	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2858	224.5	1	SNP	p	S87R	1	.	.	259	261	CGT	586	588	CGT	283;281;278	C;G;T	268;265;259	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6444	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2858	224.5	1	SNP	p	R87W	0	.	.	259	261	CGT	586	588	CGT	283;281;278	C;G;T	268;265;259	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6444	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2858	224.5	1	SNP	p	R87I	0	.	.	259	261	CGT	586	588	CGT	283;281;278	C;G;T	268;265;259	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6444	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2858	224.5	1	SNP	p	S88P	0	.	.	262	264	TCC	589	591	TCC	277;276;273	T;C;C	263;261;259	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4430	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2623	168.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1517	1519	GGC	210;210;209	G;G;C,A	197;198;191,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.35.001	penA.35.001	1	1	27	4034	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2463	163.2	1	SNP	p	A311V	0	.	.	931	933	GCC	1306	1308	GCC	233;235;236	G;C;C	219;221;220	penA.35.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4034	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2463	163.2	1	SNP	p	I312M	1	.	.	934	936	ATG	1309	1311	ATG	238;239;236	A;T;G	222;223;220	penA.35.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4034	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2463	163.2	1	SNP	p	V316T	1	.	.	946	948	ACC	1321	1323	ACC	235;233;234	A;C;C	217;220;219	penA.35.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4034	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2463	163.2	1	SNP	p	T316P	0	.	.	946	948	ACC	1321	1323	ACC	235;233;234	A;C;C	217;220;219	penA.35.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4034	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2463	163.2	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1822	1824	ACC	218;213;216	A;C,A;C	201;201,1;206	penA.35.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4034	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2463	163.2	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1876	1878	GCG	188;189;189	G;C;G	160;149;155	penA.35.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4034	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2463	163.2	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1876	1878	GCG	188;189;189	G;C;G	160;149;155	penA.35.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4034	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2463	163.2	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1999	2001	GGT	170;171;174	G;G;T,C	154;153;153,1	penA.35.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4034	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2463	163.2	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2008	2010	GGC	164;159;159	G;G;C	143;140;142	penA.35.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	4034	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2463	163.2	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2026	2028	CCG	139;140;145	C,G;C;G	110,6;114;118	penA.35.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6404	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3227	198.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1665	1667	CCG	240;240;240	C;C;G	216;217;213	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2658	porA	1146	1146	99.91	porA.l6.c17.ctg.1	1712	154.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	513	513	C	192	C	174	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3216	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1433	222.2	0	.	p	.	0	I45V	NONSYN	133	135	ATT	388	390	GTT	285;287;287	G;T;T	266;267;270	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3216	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1433	222.2	1	SNP	p	G120K	1	.	.	358	360	AAG	613	615	AAG	282;283;285	A;A;G	256;262;260	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3216	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1433	222.2	1	SNP	p	N121D	0	.	.	361	363	AAC	616	618	AAC	282;282;281	A;A;C	260;259;258	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3216	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1433	222.2	1	SNP	p	A121N	1	.	.	361	363	AAC	616	618	AAC	282;282;281	A;A;C	260;259;258	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12070	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4992	241.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1188	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1083	109.3	1	SNP	p	V57M	1	.	.	169	171	ATG	508	510	ATG	233;233;236	A;T;G	221;222;222	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
